Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Saudi Pharmaceutical Industries & Medical Appliances's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 13.71%.
SAU:2070's ROC (Joel Greenblatt) % is ranked better than 50.71% of 980
companies
in the Drug Manufacturers industry
Industry Median: 11.09
vs SAU:2070: 11.62
Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saudi Pharmaceutical Industries & Medical Appliances ROC (Joel Greenblatt) % Chart
Saudi Pharmaceutical Industries & Medical Appliances Annual Data
SAU:2070 vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Saudi Pharmaceutical Industries & Medical Appliances's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saudi Pharmaceutical Industries & Medical Appliances ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
Saudi Pharmaceutical Industries & Medical Appliances ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 13.71% mean?
Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) has a ROC (Joel Greenblatt) % of 13.71% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Saudi Pharmaceutical Industries & Medical Appliances and its competitors. This is 207% above median its historical median of 4.47. According to the industry distribution chart, Saudi Pharmaceutical Industries & Medical Appliances ranks #483 out of 980 companies in the Drug Manufacturers industry, placing it in the top 49.3%.
Is Saudi Pharmaceutical Industries & Medical Appliances' ROC (Joel Greenblatt) % too high?
Saudi Pharmaceutical Industries & Medical Appliances' current ROC (Joel Greenblatt) % of 13.71% is 207% above median its 10-year median of 4.47. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.09. Saudi Pharmaceutical Industries & Medical Appliances' value of 13.71% is 23.6% above this industry median. Based on the distribution chart, Saudi Pharmaceutical Industries & Medical Appliances ranks #483 out of 980 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Saudi Pharmaceutical Industries & Medical Appliances has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Saudi Pharmaceutical Industries & Medical Appliances' ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Saudi Pharmaceutical Industries & Medical Appliances ranks #483 out of 980 companies for ROC (Joel Greenblatt) %. This puts Saudi Pharmaceutical Industries & Medical Appliances in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.09. Saudi Pharmaceutical Industries & Medical Appliances' value of 13.71% is 23.6% above this benchmark. While the company's 10-year median is 4.47 vs. the industry median of 11.09, Saudi Pharmaceutical Industries & Medical Appliances has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.09, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saudi Pharmaceutical Industries & Medical Appliances's current ROC (Joel Greenblatt) % of 13.71% is 23.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Saudi Pharmaceutical Industries & Medical Appliances and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saudi Pharmaceutical Industries & Medical Appliances's current ROC (Joel Greenblatt) % is 13.71%, which is 207% above median its own 10-year median of 4.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saudi Pharmaceutical Industries & Medical Appliances stock overvalued right now?
Based on GuruFocus' analysis, Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) is currently considered Fairly Valued. The stock's GF Value™ is ﷼31.65, compared to a current price of ﷼31.30 — trading 1.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 13.71%, which is 207% above median its 10-year median of 4.47 and 23.6% above the Drug Manufacturers industry median of 11.09. Saudi Pharmaceutical Industries & Medical Appliances' overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070), the current ROC (Joel Greenblatt) % is 13.71% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) Overvalued in 2026?
Based on GuruFocus' analysis, Saudi Pharmaceutical Industries & Medical Appliances stock appears to be undervalued.
The current stock price of ﷼31.30 is trading 1.1% below its estimated GF Value™ of ﷼31.65.
GuruFocus considers Saudi Pharmaceutical Industries & Medical Appliances to be Fairly Valued.
Key valuation signals for SAU:2070:
ROC (Joel Greenblatt) %: 13.71% (207% above median its 10-year median of 4.47)
GF Value™: ﷼31.65 vs. price of ﷼31.30 (1.1% below fair value)
Industry Position: 23.6% above the Drug Manufacturers median (#483 of 980)
No single metric tells the full story. See the SAU:2070 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saudi Pharmaceutical Industries & Medical Appliances Corp is involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics; pharmaceutical production and wholesale and retail of medicines and related products; development and marketing of medicinal and pharmaceutical products; research and development in medical science activities; operating and maintaining the healthcare facilities and any investments in related industries. The segments of the company are Pharmaceutical Manufacturing, Trading and Distribution services, and Healthcare Services, out of which the company derives maximum revenue from the Pharmaceutical Manufacturing segment. Its geographical segments are Saudi Arabia, Egypt, the Middle East, Morocco, and Algeria.
68GF Score
Get the complete analysis for SAU:2070
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:2070 has been successfully added to your 
